perk kinase inhibitors (New York University)

N/A

Report date: 2025/03/20 09:52:20
NME

Base Information

Drug Nameperk kinase inhibitors (New York University)
Drug Alias NamePRKR-like endoplasmic reticulum kinase inhibitors (New York University)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEukaryotic Translation Initiation Factor 2 Alpha Kinase 3 inhibitors
TargetsEukaryotic Translation Initiation Factor 2 Alpha Kinase 3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNew York University
China Registration ClassN/A

Develop Information

Active CompaniesNew York University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A